Form 8-K · Current report
Corning Inc. 8-K, filed Sep 11, 2026
- Filed
- CIK
- 0000024741
- Accession no.
- 0001193125-26-389321
Summary
Corning Inc. entered into an equity distribution agreement with Goldman Sachs & Co. LLC on September 11, 2026, to sell up to $2 billion of its common stock from time to time through an "at the market" offering program, with Goldman Sachs acting as sales agent and also able to buy shares directly as principal. Corning said it intends to use net proceeds for general corporate purposes and will pay Goldman Sachs a 1.0% commission on gross proceeds of shares sold through it.
Key points
- The agreement covers shares of Corning common stock, par value $0.50 per share, with an aggregate offering price of up to $2,000,000,000.
- Sales will be made under Corning's automatically effective shelf registration statement on Form S-3 (File No. 333-295316) filed April 24, 2026, with a prospectus supplement filed September 11, 2026.
- Corning will pay Goldman Sachs a commission of 1.0% of the gross proceeds of common stock sold through Goldman Sachs under the agreement.
- Corning Vice President and Secretary Melissa J. Gambol issued an opinion dated September 11, 2026, on the validity of the shares to be issued.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
ITEM 8.01. Other Events. On September 11, 2026, Corning Incorporated (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) to sell shares of the Company’s common stock, par value $0.50 per share (the “Common Stock”), having an aggregate offering price of up to $2,000,000,000, from time to time, through an “at the market” equity offering program under which Goldman Sachs will act as sales agent. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.